TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells

Experimental Lung Research

Volumn 38, Issue 9-10, 2012, Pages 463-474

  Mohammed, Ahmed El Sayed ^a,c   Eguchi, Hidetaka ^a   Wada, Satoru ^a   Koyama, Nobuyuki ^a   Shimizu, Michio ^a   Otani, Keiko ^b   Ohtaki, Megu ^b   Tanimoto, Keiji ^b   Hiyama, Keiko ^b   Gaber, Mohammed Soliman ^c   Nishiyama, Masahiko ^a,d  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c Sohag University   (Egypt)

^d GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cisplatin chemotherapy; Microarray; NSCLC; Predictive marker

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLUTATHIONE TRANSFERASE P1; OLIGONUCLEOTIDE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ASSAY; CONTROLLED STUDY; DRUG SENSITIVITY; FBLP1 GENE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LINEAR REGRESSION ANALYSIS; LUNG NON SMALL CELL CANCER; MARKER GENE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEP WISE MULTIPLE REGRESSION; TMEM158 GENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CISPLATIN; CYTOSKELETAL PROTEINS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MEMBRANE PROTEINS; REGRESSION ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84867934089     PISSN: 01902148     EISSN: 15210499     Source Type: Journal    
DOI: 10.3109/01902148.2012.731625     Document Type: Article

References (61)

1. Bareschino MA, Schettino C, Rossi A, Maione P, Sacco PC, Zeppa R, Gridelli C: Treatment of advanced non small cell lung cancer. J Thorac Dis. 2011;3:122-133.
2. Gaughan EM, Costa DB: Genotype-driven therapies for nonsmall cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities. Ther Adv Med Oncol. 2011;3:113-125.
3. Varughese S, Jahangir KS, Simpson CE, Boulmay BC, Lopez F: A paradigm shift in the treatment of advanced non-small cell lung cancer. Am J Med Sci. 2012;344:147-150.
4. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics. CA Cancer J Clin. 2010;60:277-300.
5. Youlden DR, Cramb SM, Baade PD: The international epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol. 2008;3:819-831.
6. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH: Eastern Cooperative Oncology Group: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98. (Pubitemid 34438899)
7. NSCLC Meta-Analysis Collaborative Group: Chemotherapy in addition to supportive care improves survival in advanced nonsmall-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26:4617-4625.
8. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW Jr, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ,Wood DE, Yang SC;NCCN Non-Small Cell Lung Cancer Panel Members: Non-small cell lung cancer. J Natl Compr Canc Netw. 2010;8:740-801.
9. Azzoli CG, Temin S, Aliff T, Baker S Jr, Brahmer J, Johnson DH, Laskin JL, MastersG,Milton D, Nordquist L, Pao W, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G: 2011 Focused update of 2009 American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2011;29:3825-3831.
10. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science. 1999;286:487-491.
11. McLeod HL, Evans WE: Pharmacogenomics: unlocking the human genome for better drug therapy. Ann Rev Pharmacol Toxicol. 2001;41:101-121. (Pubitemid 32385884)
12. Gibbs JB: Mechanism-based target identification and drug discovery in cancer research. Science. 2000;287: 1969-1973. (Pubitemid 30158664)
13. NishiyamaM, EguchiH: Recent advances in cancer chemotherapy: current strategies, pharmacokinetics, and pharmacogenomics. Adv Drug Deliv Rev. 2009;6:367-368.
14. Langer CJ: Individualized therapy for patients with non-small cell lung cancer: emerging trends and challenges. Crit Rev Oncol Hematol. 2012;83:130-144.
15. Ṕerez-Soler R: Individualized therapy in non-small-cell lung cancer: future versus current clinical practice. Oncogene. 2009;28 (Suppl 1):S38-S45.
16. Hildebrandt MA, Gu J,Wu X: Pharmacogenomics of platinumbased chemotherapy inNSCLC. Expert Opin Drug Metab Toxicol. 2009;5:745-55.
17. Danesi R, Pasqualetti G, Giovannetti E, Crea F, Altavilla G, Del Tacca M, Rosell R: Pharmacogenomics in non-small-cell lung cancer chemotherapy. Adv Drug Deliv Rev. 2009;61:408-417.
18. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer. 2009;9:489-499.
19. Ohtaki M, Otani K, Satoh K, Kawamura T, Hiyama K Nishiyama M: Model-based analysis of microarray data: exploration of differentially expressed genes between two cell types based on a two-dimensional mixed normal model. Jpn J Biometrics. 2005;26:31-48.
20. Hong WS, Saijo N, Sasaki Y, Minato K, Nakano H, Nakagawa K, Fujiwara Y, Nomura K, Twentyman PR: Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int J Cancer. 1988;41:462-467. (Pubitemid 18080806)
21. Komatsu M, Hiyama K, Tanimoto K, Yunokawa M, Otani K, Ohtaki M, Hiyama E, Kigawa J, Ohwada M, Suzuki M, Nagai N, Kudo Y, NishiyamaM: Prediction of individual response to platinum/paclitaxel combination using novel marker genes in ovarian cancers. Mol Cancer Ther. 2006;5:767-775.
22. Rousseau PJ: Least median of squares regression. J Am Stat Assoc. 1984;79:871-880.
23. R Development Core Team: R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2010ISBN 3-900051-07-0, URL http://www.R-project.org/.
24. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andŕe F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC: DNA repair by ERCC1 in nonsmall-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-991. (Pubitemid 44343542)
25. Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC: The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol. 2012;9:144-155.
26. Jiang J, Liang X, Zhou X, Huang R, Chu Z, Zhan Q: ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep. 2012;39:6933-6942.
27. Pierceall WE, Olaussen KA, Rousseau V, Brambilla E, Sprott KM, Andre F, Pignon JP, Le Chevalier T, Pirker R, Jiang C, Filipits M, Chen Y, Kutok JL, Weaver DT, Ward BE, Soria JC: Cisplatin benefit is predicted by immunohistochemical analysis of DNA repair proteins in squamous cell carcinoma but not adenocarcinoma: theranostic modeling by NSCLC constituent histological subclasses. Ann Oncol. 2012;23:2245-2252.
28. Calvo SE, Tucker EJ, Compton AG, Kirby DM, Crawford G, Burtt NP, Rivas M, Guiducci C, Bruno DL, Goldberger OA, Redman MC, Wiltshire E, Wilson CJ, Altshuler D, Gabriel SB, Daly MJ, Thorburn DR, Mootha VK: High-throughput, pooled sequencing identifies mutations in NUBPL and FOXRED1 in human complex I deficiency. Nat Genet. 2010;42:851-858.
29. Sheftel AD, Stehling O, Pierik AJ, NetzDJ, Kerscher S, Els̈asser HP, Wittig I, Balk J, Brandt U, Lill R: Human ind1, an ironsulfur cluster assembly factor for respiratory complex I. MolCell Biol. 2009;29:6059-6073.
30. Bych K, Kerscher S, Netz DJ, Pierik AJ, Zwicker K, Huynen MA, Lill R, Brandt U, Balk J: The iron-sulphur protein Ind1 is required for effective complex I assembly. EMBO J. 2008;27:1736-1746.
31. Basit S, Ali G, Wasif N, Ansar M, Ahmad W: Genetic mapping of a novel hypotrichosis locus to chromosome 7p21.3-p22.3 in a Pakistani family and screening of the candidate genes. Hum Genet. 2010;128:213-220.
32. Huang YC, Schmitt M, Yang Z, Que LG, Stewart JC, Frampton MW, Devlin RB: Gene expression profile in circulating mononuclear cells after exposure to ultrafine carbon particles. Inhal Toxicol. 2010;22:835-846.
33. Zhao Y, Zhou L, Liu B, Deng Y, Wang Y, Wang Y, Huang W, Yuan W, Wang Z, Zhu C, Liu M, Wu X, Li Y: ZNF325, a novel human zinc finger protein with a RBaK-like RB-binding domain, inhibits AP-1-and SRE-mediated transcriptional activity. Biochem Biophys Res Commun. 2006;346:1191-1199. (Pubitemid 43946821)
34. Song Q, Jing H, Wu H, Zhou G, Kajiyama T, Kambara H: Gene expression analysis on a photodiode array-based bioluminescence analyzer by using sensitivity-improved SRPP. Analyst. 2010;135:1315-1319.
35. Takafuta T, Saeki M, Fujimoto TT, Fujimura K, Shapiro SS: A new member of the LIM protein family binds to filamin B and localizes at stress fibers. J Biol Chem. 2003;278:12175-12181. (Pubitemid 36800197)
36. Tu Y,Wu S, ShiX,ChenK,WuC:Migfilin andMig-2 link focal adhesions to filamin and the actin cytoskeleton and function in cell shape modulation. Cell. 2003;113:37-47. (Pubitemid 36411958)
37. Wu C: Migfilin and its binding partners: from cell biology to human diseases. J Cell Sci. 2005;118(Pt 4):659-664. (Pubitemid 40372575)
38. Zhao J, Zhang Y, Ithychanda SS, Tu Y, Chen K, Qin J, Wu C: Migfilin interacts with Src and contributes to cellmatrix adhesion-mediated survival signaling. J Biol Chem. 2009;284:34308-34320.
39. Chou CH, Chou AK, Lin CC, Chen WJ, Wei CC, Yang MC, Hsu CM, Lung FW, Loh JK, Howng SL, Hong YR: GSK3β regulates Bcl2L12 and Bcl2L12A anti-apoptosis signaling in glioblastoma and is inhibited by LiCl. Cell Cycle. 2012;11:532-542.
40. Doble BW,Woodgett JR: GSK-3: tricks of the trade for a multitasking kinase. J. Cell Sci. 2003;116:1175-1186. (Pubitemid 36410657)
41. Grimes CA, Jope RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Pro Neurobiol. 2001;65:391-426. (Pubitemid 32781670)
42. Zhang D, Guo M, Zhang W, Lu XY: Adiponectin stimulates proliferation of adult hippocampal neural stem/progenitor cells through activation of p38 mitogen-activated protein kinase (p38MAPK)/glycogen synthase kinase 3β (GSK-3β)/β-catenin signaling cascade. J Biol Chem. 2011;286:44913-44920.
43. Beurel E, Kornprobst M, Blivet-Van Eggelpöel MJ, Ruiz-Ruiz C, Cadoret A, Capeau J, Desbois-Mouthon C: GSK-3beta inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression. Exp Cell Res. 2004;300:354-364. (Pubitemid 39314425)
44. Dong J, Peng J, Zhang H, Mondesire WH, Jian W, Mills GB, Hung MC, Meric-Bernstam F: Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity. Cancer Res. 2005;65:1961-1972. (Pubitemid 40478626)
45. Ding Q, He X, Hsu JM, Xia W, Chen CT, Li LY, Lee DF, Liu JC, Zhong Q, Wang X, Hung MC: Degradation of Mcl-1 by beta-TrCP mediates glycogen synthase kinase 3-induced tumor suppression and chemosensitization. Mol Cell Biol. 2007;27:4006-4017. (Pubitemid 47010998)
46. Kwok JB, Loy CT, Hamilton G, Lau E, Hallupp M, Williams J, Owen MJ, Broe GA, Tang N, Lam L, Powell JF, Lovestone S, Schofield PR: Glycogen synthase kinase-3beta and tau genes interact in Alzheimer's disease. Ann Neurol. 2008;64:446-454.
47. Barradas M, Gonos ES, Zebedee Z, Kolettas E, Petropoulou C, Delgado MD, Léon J, Hara E, SerranoM.Marta Barradas, Efstathios S.Gonos: Identification of a candidate tumor-suppressor gene specifically activated during Ras-induced senescence. Exp Cell Res. 2002;273:127-137. (Pubitemid 34920663)
48. Silva J, Silva JM, Barradas M, Garć?a JM,Doḿ?nguez G, Garć?a V, Pe ña C, Gallego I, Espinosa R, Serrano M, Bonilla F: Analysis of the candidate tumor suppressor Ris-1 in primary human breast carcinomas. Mutat Res. 2006;594:78-85. (Pubitemid 43170988)
49. Birch AH, Quinn MC, Filali-Mouhim A, Provencher DM, Mes-Masson AM, Tonin PN: Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes. Mol Carcinog. 2008;47:56-65.
50. Iglesias D, Ferńandez-Peralta AM, Nejda N, Daimiel L, Azcoita MM, Oliart S, Gonźalez-Aguilera JJ: RIS1, a gene with trinucleotide repeats, is a target in the mutator pathway of colorectal carcinogenesis. Cancer Genet Cytogenet. 2006;167: 138-144. (Pubitemid 43776952)
51. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 2004;22:2594-2601. (Pubitemid 41103746)
52. Tanaka T, Tanimoto K, Otani K, Satoh K, Ohtaki M, Yoshida K, Toge T, Yahata H, Tanaka S, Chayama K, Okazaki Y, Hayashizaki Y, Hiyama K, Nishiyama M: Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004;111:617-626. (Pubitemid 39045331)
53. Ichikawa W, Takahashi T, Suto K, Shirota Y, Nihei Z, Shimizu M, Sasaki Y, Hirayama R: Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer. 2006;119:1927-1933. (Pubitemid 44356853)
54. Shimizu J, Horio Y, Osada H, Hida T, Hasegawa Y, Shimokata K, Takahashi T, Sekido Y, Yatabe Y: mRNA expression of RRM1, ERCC1 and ERCC2 is not associated with chemosensitivity to cisplatin, carboplatin and gemcitabine in human lung cancer cell lines. Respirology. 2008;13:510-517. (Pubitemid 351725293)
55. Singh S, Okamura T, Ali-Osman F: Serine phosphorylation of glutathione S-transferase P1 (GSTP1) by PKCα enhances GSTP1-dependent cisplatin metabolism and resistance in human glioma cells. Biochem Pharmacol. 2010;80:1343-1355.
56. Okamura T, Singh S, Buolamwini J, Haystead T, Friedman H, Bigner D, Ali-Osman F: Tyrosine phosphorylation of the human glutathione S-transferase P1 by epidermal growth factor receptor. J Biol Chem. 2009;284:16979-16989.
57. Zhang X, Zhu J, Xing R, Tie Y, Fu H, Zheng X, Yu B: miR-513a-3p sensitizes human lung adenocarcinoma cells to chemotherapy by targeting GSTP1. Lung Cancer. 2012;77:488-494.
58. Wang Q, Zhong M, Liu W, Li J, Huang J, Zheng L: Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res. 2011;37:427-434.
59. Ballou LM, Lin RZ: Rapamycin and mTOR kinase inhibitors. J Chem Biol. 2008;1:27-36.
60. Moyer AM, Salavaggione OE, Wu TY, Moon I, Eckloff BW, Hildebrandt MA, Schaid DJ, Wieben ED, Weinshilboum RM: Glutathione s-transferase p1: gene sequence variation and functional genomic studies. Cancer Res. 2008;68:4791-4801.
61. Fumoto S, Shimokuni T, Tanimoto K, Hiyama K, Otani K, Ohtaki M, Hihara J, Yoshida K, Hiyama E, Noguchi T, Nishiyama M: Selection of a novel drug-response predictor in esophageal cancer: a novel screening method using microarray and identification of IFITM1 as a potent marker gene of CDDP response. Int J Oncol. 2008;32:413-423. (Pubitemid 351188308)